2.18  0.02 (0.93%)		08-30 15:59
Open: 2.16 High: 2.181 Volume: 2,150,077		Pre. Close: 2.16 Low: 2.13 Market Cap: 135(M)

Short term
Mid term
Targets	6-month :	2.54	1-year :	2.97
Resists	First :	2.18	Second :	2.54
Pivot price	2.15
Supports	First :	2.1	Second :	2.05
MAs	MA(5) :	2.16	MA(20) :	2.13
	MA(100) :	1.97	MA(250) :	1.71
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	69.4	D(3) :	73.8
RSI	RSI(14): 65.1
52-week	High :	3.19	Low :	0.75

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PRDS ] has closed below upper band by 34.3%. Bollinger Bands are 71.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.16 - 2.17	2.17 - 2.18
Low:	2.13 - 2.15	2.15 - 2.16
Close:	2.14 - 2.16	2.16 - 2.18

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Mon, 28 Aug 2023
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences - Business Wire

Mon, 17 Jul 2023
Pardes changes hands (sort of) in wake of COVID trial fail - Fierce Biotech

Tue, 02 May 2023
Pardes Biosciences: Strategic Review Is Likely To End Up In A Privatization (NASDAQ:PRDS) - Seeking Alpha

Fri, 21 Apr 2023
Pardes Biosciences stock jumps after original SPAC sponsor makes takeover offer - Seeking Alpha

Mon, 03 Apr 2023
Pardes Biosciences to suspend COVID-19 drug development after mid-stage trial fails - Reuters

Fri, 04 Mar 2022
Covid drug hopeful turns to biotech vet who sold last company for $1 billlion - San Francisco Business Times - The Business Journals

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	62 (M)
Shares Float	14 (M)
Held by Insiders	13.4 (%)
Held by Institutions	72 (%)
Shares Short	874 (K)
Shares Short P.Month	1,040 (K)

EPS	-1.28
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.56
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-26.5 %
Return on Equity (ttm)	-40.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-79 (M)
Levered Free Cash Flow	-51 (M)

PE Ratio	-1.69
PEG Ratio	0
Price to Book value	0.84
Price to Sales	0
Price to Cash Flow	-1.71

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.